Novo Nordisk

Novo Nordisk
Share

Novo Nordisk

 •  December 6, 2017

Today the International Diabetes Federation (IDF) presented the interim results of the first ever multi-country online survey on CVD risk awareness and knowledge among people living with type 2 diabetes, indicating low levels of awareness and limited dialogue between patients and healthcare professionals. The global survey - Taking Diabetes to...

Novo Nordisk

 •  December 5, 2017

Xultophy® reported a better option than basal-bolus insulin therapy to manage type 2 diabetes by participants in the DUAL VII clinical trial Abu Dhabi, UAE, 5 December 2017 - Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen). This was...

Novo Nordisk

 •  December 5, 2017

Switching to Tresiba® benefits people with diabetes irrespective of blood sugar levels in a real-world setting Switching to Tresiba® reduced the rate of hypoglycaemia by 67% in people with controlled blood sugar levels In people with diabetes whose blood sugar was too high, switching to Tresiba® significantly improved blood sugar levels Bagsværd,...

Novo Nordisk

 •  December 5, 2017

Ozempic® (semaglutide) approved in the US Bagsværd, Denmark, 5 December 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Ozempic® (semaglutide injection). Ozempic® is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Ozempic®, the...

Novo Nordisk

 •  August 28, 2017

Victoza® reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events Barcelona, Spain, 28 August 2017 - A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of...

Novo Nordisk

 •  July 27, 2017

Novo Nordisk A/S: Victoza® has been approved in the EU as the only GLP-1 with a label to include prevention of cardiovascular events Bagsværd, Denmark, 27 July 2017 - The European Commission has approved an update to the Victoza® (liraglutide) EU label that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events...

Novo Nordisk

 •  June 16, 2017

FDA posts briefing materials prior to Advisory Committee meeting for Victoza® label update Bagsværd, Denmark, 16 June 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss the supplemental New Drug Application (sNDA) for approval of...

Novo Nordisk

 •  March 27, 2017

Fiasp®, a new, ultra-fast acting mealtime insulin is available for the treatment of diabetes in adults Canada first country to launch Fiasp® Bagsværd, Denmark, 27 March 2017 ­­­- Today, Novo Nordisk announced that Fiasp®, a new, fast-acting mealtime insulin for the treatment of diabetes in adults, has been launched in Canada, following the recent...

Novo Nordisk

 •  December 5, 2016

Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US and EU for the treatment of type 2 diabetes Bagsværd, Denmark, 5 December 2016 - Novo Nordisk today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European...

Novo Nordisk

 •  November 29, 2016

Novo Nordisk A/S: Tresiba® demonstrates a safe cardiovascular profile and reduces the risk of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial Bagsværd, 29 November 2016 - Today, Novo Nordisk announced the headline results from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to...